Retatrutide 10mg
Next-gen triple agonist peptide
Retatrutide is an experimental triple-agonist peptide attracting strong interest in the research community for its mechanism acting on three receptors simultaneously (GLP-1, GIP and glucagon). Each vial contains 10mg of lyophilised (freeze-dried) peptide and ships with an independent test report.
Secure payment via Stripe
- Contents
- 10mg
- Purity
- 99.8%
- Form
- Lyophilised powder
- Intended use
- Research purposes
For research purposes only — not for human consumption.
Product highlights
- 99.80% purity — independently tested by Vanguard Laboratory
- 10mg lyophilised peptide per vial
- Triple agonist: GLP-1 / GIP / glucagon receptors
- Supplied with a verifiable Certificate of Analysis
- For laboratory and research use only
Storage & handling
Store at 2–8°C, dark and dry. Do not freeze. Refrigerate after reconstitution.
Research context
Retatrutide (development code LY3437943) is studied in published clinical trials (including phase 2 research published in The New England Journal of Medicine, 2023) within metabolic research. We sell this product solely as a research reference material and make no claims regarding suitability for human or animal use.
Test report
Independent test report available
- Lab
- Vanguard Laboratory
- Purity
- >99.80%
- Content
- 11.00 mg
- Lot
- RETA012026-10
